JSPR – jasper therapeutics, inc. - class a (US:NASDAQ)
Jasper Therapeutics, Inc. (NASDAQ: JSPR) is now covered by analysts at UBS Group AG. They set a "buy" rating and a $38.00 price target on the stock.
Jasper Therapeutics Announces Briquilimab Presentations at the American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Meeting
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference [Yahoo! Finance]
Jasper Therapeutics to Present at the Oppenheimer Healthcare Life Sciences Conference
Jasper Therapeutics, Inc. (NASDAQ: JSPR) had its price target lowered by analysts at HC Wainwright from $60.00 to $40.00. They now have a "buy" rating on the stock.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com